RedHill’s Opaganib Gains FDA Rare Pediatric Disease Status
RALEIGH, North Carolina, USA & TEL AVIV, Israel – June 9, 2026 RedHill Biopharma has received a significant regulatory...
Oncology drug development
Advertisement
SystImmune’s BL-M14D1 Shows Strong Activity in SCLC
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Advertisements
Parexel Showcases Oncology Research and Patient-Centered Innovation at ASCO 2026
RALEIGH, N.C. | May 28, 2026 Parexel announced that two oncology-focused research posters have been accepted for presentation at...
Nuvalent Expands Leadership in Precision Lung Cancer
CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...
Dizal Advances ZEGFROVY for EGFR Lung Cancer
SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...
GSK Partners With SBP Group to Expand Hepatitis B Treatment
LONDON, UK – May 11, 2026 GSK plc announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) through...
Innovent Secures Third NMPA Breakthrough Status for IBI363
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
Advertisement
